SOX6 and neoplasm: Previous studies have shown that SOX6 is downregulated and serves as a tumor growth inhibitor in many cancers, including breast cancer, lung adenocarcinoma, osteosarcoma, prostate cancer, and esophageal cancer (Chen et al., 2020; Wang et al., 2016; Zhang et al., 2021).